Last 12 months
Inside the activity.
0 purchase rows · 35 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 8 |
| Dec 2025 | 0 | 2 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 16 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 2 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 28, 2021 Filed Dec 30, 2021 22:00 UTC |
Virgin HerbertEVP, Research & CSO
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,375 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-21-071611 · doc4.xml · derivative · entry 3 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,005 Underlying: Common Stock · 1,375 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| December 28, 2021 Filed Dec 30, 2021 22:00 UTC |
Virgin HerbertEVP, Research & CSO
|
SaleCommon Stock | 1,375 | $39.95 | $54,931.25 |
DisclosureSEC source: 0001209191-21-071611 · doc4.xml · nonDerivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2021. Read SEC document |
| December 28, 2021 Filed Dec 30, 2021 22:00 UTC |
Virgin HerbertEVP, Research & CSO
|
Exercise / conversionCommon Stock | 1,375 | $1.53 | $2,103.75 |
DisclosureSEC source: 0001209191-21-071611 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,075 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 20, 2021 Filed Dec 21, 2021 23:13 UTC |
SATO VICKI LDirector
|
SaleCommon Stock | 2,401 | $57.82 | $138,825.82 |
DisclosureSEC source: 0001209191-21-070835 · doc4.xml · nonDerivative · entry 5 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,551,092 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021. Read SEC document |
| December 20, 2021 Filed Dec 21, 2021 23:13 UTC |
SATO VICKI LDirector
|
SaleCommon Stock | 1,100 | $56.10 | $61,714.95 |
DisclosureSEC source: 0001209191-21-070835 · doc4.xml · nonDerivative · entry 4 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,553,493 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.06 to $56.21, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| December 20, 2021 Filed Dec 21, 2021 23:13 UTC |
SATO VICKI LDirector
|
SaleCommon Stock | 5,200 | $55.38 | $287,993.16 |
DisclosureSEC source: 0001209191-21-070835 · doc4.xml · nonDerivative · entry 3 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,554,593 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.00 to $55.81, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| December 20, 2021 Filed Dec 21, 2021 23:13 UTC |
SATO VICKI LDirector
|
SaleCommon Stock | 1,300 | $54.35 | $70,652.01 |
DisclosureSEC source: 0001209191-21-070835 · doc4.xml · nonDerivative · entry 2 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,559,793 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.00 to $54.62, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| December 20, 2021 Filed Dec 21, 2021 23:13 UTC |
SATO VICKI LDirector
|
SaleCommon Stock | 5,173 | $51.87 | $268,298.68 |
DisclosureSEC source: 0001209191-21-070835 · doc4.xml · nonDerivative · entry 1 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,561,093 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.70 to $52.115, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| December 20, 2021 Filed Dec 22, 2021 16:30 UTC |
SVF Endurance (Cayman) Ltd10% owner
SB INVESTMENT ADVISERS (UK) LTD10% owner
SOFTBANK VISION FUND (AIV M1) L.P.10% owner
|
SaleCommon Stock | 400,022 | $52.73 | $21,093,160.06 |
DisclosureSEC source: 0000899243-21-049394 · doc4.xml · nonDerivative · entry 1 SVF Endurance (Cayman) Ltd · CIK 0001782338 · 10% owner SB INVESTMENT ADVISERS (UK) LTD · CIK 0001731509 · 10% owner SOFTBANK VISION FUND (AIV M1) L.P. · CIK 0001755143 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 22,216,644 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.90 to $57.82. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments Read SEC document |
| December 20, 2021 Filed Dec 22, 2021 23:00 UTC |
NELSEN ROBERTDirector · 10% owner
|
OtherCommon Stock | 102,041 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-013386 · form4.xml · nonDerivative · entry 3 NELSEN ROBERT · CIK 0001219042 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,172 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4 · kind: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. Read SEC document |
| December 20, 2021 Filed Dec 22, 2021 23:00 UTC |
NELSEN ROBERTDirector · 10% owner
|
OtherCommon Stock | 987,767 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-013386 · form4.xml · nonDerivative · entry 2 NELSEN ROBERT · CIK 0001219042 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 10,677,283 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F3 · ownership.nature: The shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). The Reporting Person is a managing director of ARCH Venture Partners IX, LLC, the sole general partner of ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), which is the sole general partner of ARCH Overage, and shares voting and investment control with respect to shares held by ARCH Overage. The Reporting Person disclaims ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| December 20, 2021 Filed Dec 22, 2021 23:00 UTC |
NELSEN ROBERTDirector · 10% owner
|
OtherCommon Stock | 762,233 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-013386 · form4.xml · nonDerivative · entry 1 NELSEN ROBERT · CIK 0001219042 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 8,239,380 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F2 · ownership.nature: The shares are held by ARCH Venture Fund IX, L.P. ("ARCH IX"). The Reporting Person is a managing director of ARCH Venture Partners IX, LLC, the sole general partner of ARCH Venture Partners IX, L.P., which is the sole general partner of ARCH IX, and shares voting and investment control with respect to shares held by ARCH IX. The Reporting Person may be deemed to beneficially own the shares held by ARCH IX, and the Reporting Person disclaims ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| December 20, 2021 Filed Dec 22, 2021 22:59 UTC |
ARCH Venture Partners IX, LLC10% owner
ARCH Venture Partners IX, L.P.10% owner
ARCH Venture Fund IX, L.P.10% owner
ARCH Venture Fund IX Overage, L.P.10% owner
CRANDELL KEITH10% owner
BYBEE CLINTON10% owner
|
OtherCommon Stock | 15,504 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-013385 · form4.xml · nonDerivative · entry 4 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,589 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4 · kind: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F6 · ownership.direct: Shares held directly by Bybee. Read SEC document |
| December 20, 2021 Filed Dec 22, 2021 22:59 UTC |
ARCH Venture Partners IX, LLC10% owner
ARCH Venture Partners IX, L.P.10% owner
ARCH Venture Fund IX, L.P.10% owner
ARCH Venture Fund IX Overage, L.P.10% owner
CRANDELL KEITH10% owner
BYBEE CLINTON10% owner
|
OtherCommon Stock | 45,703 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-013385 · form4.xml · nonDerivative · entry 3 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,058 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4 · kind: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F5 · ownership.direct: Shares held directly by Crandell. Read SEC document |
| December 20, 2021 Filed Dec 22, 2021 22:59 UTC |
ARCH Venture Partners IX, LLC10% owner
ARCH Venture Partners IX, L.P.10% owner
ARCH Venture Fund IX, L.P.10% owner
ARCH Venture Fund IX Overage, L.P.10% owner
CRANDELL KEITH10% owner
BYBEE CLINTON10% owner
|
OtherCommon Stock | 987,767 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-013385 · form4.xml · nonDerivative · entry 2 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 10,677,283 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F3 · ownership.nature: These shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. GPLLC, as the sole general partner of Overage GPLP, may be deemed to beneficially own the shares held by ARCH Overage. As managing directors of GPLLC, each of the ARCH Managing Directors may be deemed to beneficially own the shares held by ARCH Overage. Each of Overage GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. Read SEC document |
| December 20, 2021 Filed Dec 22, 2021 22:59 UTC |
ARCH Venture Partners IX, LLC10% owner
ARCH Venture Partners IX, L.P.10% owner
ARCH Venture Fund IX, L.P.10% owner
ARCH Venture Fund IX Overage, L.P.10% owner
CRANDELL KEITH10% owner
BYBEE CLINTON10% owner
|
OtherCommon Stock | 762,233 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-013385 · form4.xml · nonDerivative · entry 1 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 8,239,380 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F2 · ownership.nature: These shares are directly held by ARCH Venture Fund IX, L.P. ("ARCH IX"). ARCH Venture Partners IX, L.P. ("GPLP"), as the sole general partner of ARCH IX, may be deemed to beneficially own the shares held by ARCH IX. ARCH Venture Partners IX, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by ARCH IX. As managing directors of GPLLC, each of Keith Crandell and Clinton Bybee (the "ARCH Managing Directors"), may be deemed to beneficially own the shares held by ARCH IX. Each of GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. Read SEC document |
| December 20, 2021 Filed May 10, 2022 21:26 UTC Amendment |
NELSEN ROBERTDirector · 10% owner
|
OtherCommon Stock | 102,041 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-012007 · form4a.xml · nonDerivative · entry 1 NELSEN ROBERT · CIK 0001219042 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,546 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F2 · kind: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F3 · ownership.direct: Correction made to include shares previously reported in prior filing on 5/21/21 but not included in the amount of shares beneficially owned in subsequent filings. Read SEC document |
| December 15, 2021 Filed Dec 16, 2021 22:04 UTC |
Virgin HerbertEVP, Research & CSO
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,750 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-21-069994 · doc4.xml · derivative · entry 6 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,380 Underlying: Common Stock · 2,750 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| December 15, 2021 Filed Dec 16, 2021 22:04 UTC |
Virgin HerbertEVP, Research & CSO
|
SaleCommon Stock | 2,750 | $50.00 | $137,500.00 |
DisclosureSEC source: 0001209191-21-069994 · doc4.xml · nonDerivative · entry 4 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2021. Read SEC document |
| December 15, 2021 Filed Dec 16, 2021 22:04 UTC |
Virgin HerbertEVP, Research & CSO
|
Exercise / conversionCommon Stock | 2,750 | $1.53 | $4,207.50 |
DisclosureSEC source: 0001209191-21-069994 · doc4.xml · nonDerivative · entry 3 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,450 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 22:01 UTC |
Pang PhillipChief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-21-070325 · doc4.xml · derivative · entry 6 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,591 Underlying: Common Stock · 5,000 shares Expires 2018-04-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on April 27, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 22:01 UTC |
Pang PhillipChief Medical Officer
|
SaleCommon Stock | 1,200 | $52.20 | $62,640.48 |
DisclosureSEC source: 0001209191-21-070325 · doc4.xml · nonDerivative · entry 5 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,777 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021. F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.01 to $52.59 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 22:01 UTC |
Pang PhillipChief Medical Officer
|
SaleCommon Stock | 1,034 | $51.30 | $53,039.75 |
DisclosureSEC source: 0001209191-21-070325 · doc4.xml · nonDerivative · entry 4 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,977 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00 to $51.95 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 22:01 UTC |
Pang PhillipChief Medical Officer
|
SaleCommon Stock | 1,050 | $50.60 | $53,133.15 |
DisclosureSEC source: 0001209191-21-070325 · doc4.xml · nonDerivative · entry 3 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,011 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.9825 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 22:01 UTC |
Pang PhillipChief Medical Officer
|
SaleCommon Stock | 1,716 | $49.41 | $84,794.77 |
DisclosureSEC source: 0001209191-21-070325 · doc4.xml · nonDerivative · entry 2 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,061 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.91 to $49.83 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 22:01 UTC |
Pang PhillipChief Medical Officer
|
Exercise / conversionCommon Stock | 5,000 | $1.53 | $7,650.00 |
DisclosureSEC source: 0001209191-21-070325 · doc4.xml · nonDerivative · entry 1 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,777 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 22:04 UTC |
Virgin HerbertEVP, Research & CSO
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,375 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-21-069994 · doc4.xml · derivative · entry 5 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,130 Underlying: Common Stock · 1,375 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 22:04 UTC |
Virgin HerbertEVP, Research & CSO
|
SaleCommon Stock | 1,375 | $45.88 | $63,085.00 |
DisclosureSEC source: 0001209191-21-069994 · doc4.xml · nonDerivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2021. Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 22:04 UTC |
Virgin HerbertEVP, Research & CSO
|
Exercise / conversionCommon Stock | 1,375 | $1.53 | $2,103.75 |
DisclosureSEC source: 0001209191-21-069994 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,075 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:22 UTC |
Pang PhillipChief Medical Officer
|
SaleCommon Stock | 91 | $44.97 | $4,092.27 |
DisclosureSEC source: 0001209191-21-067918 · doc4.xml · nonDerivative · entry 4 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,777 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:22 UTC |
Pang PhillipChief Medical Officer
|
SaleCommon Stock | 2,050 | $44.10 | $90,405.00 |
DisclosureSEC source: 0001209191-21-067918 · doc4.xml · nonDerivative · entry 3 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,868 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.84 to $44.49 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:22 UTC |
Pang PhillipChief Medical Officer
|
SaleCommon Stock | 4,409 | $43.46 | $191,615.14 |
DisclosureSEC source: 0001209191-21-067918 · doc4.xml · nonDerivative · entry 2 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,918 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.83 to $43.81 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:22 UTC |
Pang PhillipChief Medical Officer
|
SaleCommon Stock | 950 | $41.82 | $39,729.00 |
DisclosureSEC source: 0001209191-21-067918 · doc4.xml · nonDerivative · entry 1 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,327 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.41 to $42.31 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 22:12 UTC |
Virgin HerbertEVP, Research & CSO
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 15,125 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-21-067659 · doc4.xml · derivative · entry 4 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,505 Underlying: Common Stock · 15,125 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 22:12 UTC |
Virgin HerbertEVP, Research & CSO
|
SaleCommon Stock | 13,750 | $50.00 | $687,500.00 |
DisclosureSEC source: 0001209191-21-067659 · doc4.xml · nonDerivative · entry 3 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2021. Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 22:12 UTC |
Virgin HerbertEVP, Research & CSO
|
SaleCommon Stock | 1,375 | $45.60 | $62,700.00 |
DisclosureSEC source: 0001209191-21-067659 · doc4.xml · nonDerivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,450 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2021. Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 22:12 UTC |
Virgin HerbertEVP, Research & CSO
|
Exercise / conversionCommon Stock | 15,125 | $1.53 | $23,141.25 |
DisclosureSEC source: 0001209191-21-067659 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,825 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 22:12 UTC |
Rice Steven J.Chief Administrative Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $12.76 | $0.00 |
DisclosureSEC source: 0001209191-21-067656 · doc4.xml · derivative · entry 3 Rice Steven J. · CIK 0001820108 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 424,441 Underlying: Common Stock · 10,000 shares Expires 2029-12-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the stock option vest and become exercisable on September 15, 2020, and the remainder vest in 36 equal monthly installments thereafter. Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 22:12 UTC |
Rice Steven J.Chief Administrative Officer
|
SaleCommon Stock | 10,000 | $50.00 | $500,000.00 |
DisclosureSEC source: 0001209191-21-067656 · doc4.xml · nonDerivative · entry 2 Rice Steven J. · CIK 0001820108 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,600 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021. Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 22:12 UTC |
Rice Steven J.Chief Administrative Officer
|
Exercise / conversionCommon Stock | 10,000 | $12.76 | $127,600.00 |
DisclosureSEC source: 0001209191-21-067656 · doc4.xml · nonDerivative · entry 1 Rice Steven J. · CIK 0001820108 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 600 shares of common stock acquired by the reporting person on November 30, 2021 pursuant to an employee stock purchase program. Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 22:10 UTC |
Napolitano JanetDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,435 | $0.00 Strike: $41.64 | $0.00 |
DisclosureSEC source: 0001209191-21-067655 · doc4.xml · derivative · entry 3 Napolitano Janet · CIK 0001821008 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,130 Underlying: Common Stock · 1,435 shares Expires 2030-08-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/3 of the shares subject to the stock option vested and became exercisable on August 28, 2021, and the remaining shares vest in 24 equal monthly installments thereafter. Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 22:10 UTC |
Napolitano JanetDirector
|
SaleCommon Stock | 1,435 | $46.25 | $66,368.75 |
DisclosureSEC source: 0001209191-21-067655 · doc4.xml · nonDerivative · entry 2 Napolitano Janet · CIK 0001821008 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,374 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 2, 2021. Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 22:10 UTC |
Napolitano JanetDirector
|
Exercise / conversionCommon Stock | 1,435 | $41.64 | $59,753.40 |
DisclosureSEC source: 0001209191-21-067655 · doc4.xml · nonDerivative · entry 1 Napolitano Janet · CIK 0001821008 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,809 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 29, 2021 Filed Dec 1, 2021 20:20 UTC |
HANLY ANN M.Chief Technology Officer
|
PurchaseCommon Stock | 11.52 | $43.39 | $499.85 |
DisclosureSEC source: 0001209191-21-067380 · doc4.xml · nonDerivative · entry 1 HANLY ANN M. · CIK 0001854528 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 11.52 F1 · ownership.nature: The purchase was effectuated by a minor through a trading account registered in the name of the reporting person's spouse. Read SEC document |
| November 29, 2021 Filed Dec 1, 2021 23:30 UTC |
ARCH Venture Partners IX, LLC10% owner
ARCH Venture Partners IX, L.P.10% owner
ARCH Venture Fund IX, L.P.10% owner
ARCH Venture Fund IX Overage, L.P.10% owner
CRANDELL KEITH10% owner
BYBEE CLINTON10% owner
|
OtherCommon Stock | 4,428 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-011917 · form4.xml · nonDerivative · entry 4 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,085 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4 · kind: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F6 · ownership.direct: Shares held directly by Bybee. Read SEC document |
| November 29, 2021 Filed Dec 1, 2021 23:30 UTC |
ARCH Venture Partners IX, LLC10% owner
ARCH Venture Partners IX, L.P.10% owner
ARCH Venture Fund IX, L.P.10% owner
ARCH Venture Fund IX Overage, L.P.10% owner
CRANDELL KEITH10% owner
BYBEE CLINTON10% owner
|
OtherCommon Stock | 13,057 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-011917 · form4.xml · nonDerivative · entry 3 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,355 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4 · kind: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F5 · ownership.direct: Shares held directly by Crandell. Read SEC document |
| November 29, 2021 Filed Dec 1, 2021 23:30 UTC |
ARCH Venture Partners IX, LLC10% owner
ARCH Venture Partners IX, L.P.10% owner
ARCH Venture Fund IX, L.P.10% owner
ARCH Venture Fund IX Overage, L.P.10% owner
CRANDELL KEITH10% owner
BYBEE CLINTON10% owner
|
OtherCommon Stock | 282,219 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-011917 · form4.xml · nonDerivative · entry 2 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 11,665,050 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F3 · ownership.nature: These shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. GPLLC, as the sole general partner of Overage GPLP, may be deemed to beneficially own the shares held by ARCH Overage. As managing directors of GPLLC, each of the ARCH Managing Directors may be deemed to beneficially own the shares held by ARCH Overage. Each of Overage GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. Read SEC document |
| November 29, 2021 Filed Dec 1, 2021 23:30 UTC |
ARCH Venture Partners IX, LLC10% owner
ARCH Venture Partners IX, L.P.10% owner
ARCH Venture Fund IX, L.P.10% owner
ARCH Venture Fund IX Overage, L.P.10% owner
CRANDELL KEITH10% owner
BYBEE CLINTON10% owner
|
OtherCommon Stock | 217,781 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-011917 · form4.xml · nonDerivative · entry 1 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 9,001,613 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F2 · ownership.nature: These shares are directly held by ARCH Venture Fund IX, L.P. ("ARCH IX"). ARCH Venture Partners IX, L.P. ("GPLP"), as the sole general partner of ARCH IX, may be deemed to beneficially own the shares held by ARCH IX. ARCH Venture Partners IX, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by ARCH IX. As managing directors of GPLLC, each of Keith Crandell and Clinton Bybee (the "ARCH Managing Directors"), may be deemed to beneficially own the shares held by ARCH IX. Each of GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. Read SEC document |
| November 29, 2021 Filed Dec 1, 2021 23:31 UTC |
NELSEN ROBERTDirector · 10% owner
|
OtherCommon Stock | 29,153 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-011919 · form4.xml · nonDerivative · entry 3 NELSEN ROBERT · CIK 0001219042 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,131 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4 · kind: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. Read SEC document |
| November 29, 2021 Filed Dec 1, 2021 23:31 UTC |
NELSEN ROBERTDirector · 10% owner
|
OtherCommon Stock | 282,219 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-011919 · form4.xml · nonDerivative · entry 2 NELSEN ROBERT · CIK 0001219042 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 11,665,050 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F3 · ownership.nature: The shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). The Reporting Person is a managing director of ARCH Venture Partners IX, LLC, the sole general partner of ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), which is the sole general partner of ARCH Overage, and shares voting and investment control with respect to shares held by ARCH Overage. The Reporting Person disclaims ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.